Importantly, we provide both in vitro and in vivo preclinical experimental evidences to show the efficiency of CLU silencer (OGX‐011) and PRKDs inhibitor (CRT0066101) treatment in TNBC tumor growth suppression, suggesting targeting CLU pathway will be promisingly efficient for treatment of TNBC. Here, CLU is linked to neoplasm.